Race Oncology Ltd. (AU:RAC)

ASX:RAC

RAC

Race Oncology Ltd.

RESEARCH TOOLSreports

Want to see AU:RAC full AI Analyst Report?

Race Oncology Ltd. (RAC) Price & Analysis

36 Followers

RAC Stock Chart & Stats

AU$2.70

-AU$0.03(-2.27%)

At close: Jan 09 4:00 PM EST

AU$2.70

-AU$0.03(-2.27%)

Day’s Range― - ―

52-Week RangeAU$1.12 - AU$4.90

Previous CloseN/A

Volume68.10K

Average Volume (3M)373.28K

Market Cap

AU$538.29M

Enterprise ValueAU$475.22M

Total Cash (Recent Filing)AU$20.94M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.59

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding195,033,420

10 Day Avg. Volume310,625

30 Day Avg. Volume373,283

Financial Highlights & Ratios

PEG Ratio0.63

Price to Book (P/B)12.69

Price to Sales (P/S)33.63

P/FCF Ratio-44.42

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.04

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero debt materially lowers refinancing and interest-rate risk and preserves financial flexibility to fund clinical programs. Over the next 2-6 months this conservatism supports sustained R&D activity and reduces short-term solvency pressure versus leveraged peers.

Focused, Differentiated Clinical AssetA clear strategic focus on a single repurposed oncology compound concentrates expertise and resource allocation, improving execution odds in trials. Structural specialization can drive program-level value creation if clinical readouts progress, and supports targeted partnership or licensing opportunities.

Improved Gross Margin And Cost PerformanceA materially stronger gross margin in FY2025 signals improved revenue quality or lower variable costs, enhancing operating leverage. If maintained, higher gross margins make future scaling more profitable and reduce the incremental funding needed per dollar of revenue growth.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow indicate the business is not self-funding and will require external financing. Over months this raises dilution and execution risk for clinical programs, and constrains ability to opportunistically invest in trials or partnerships without raising capital.

Ongoing UnprofitabilitySustained operating losses and negative net margins show the company has not yet translated activities into profit. Persisting unprofitability depresses returns on equity and undermines long-term shareholder value absent clear paths to scalable revenue or successful clinical outcomes.

Revenue Volatility And Recent DeclineSharp, uneven revenue trends reduce predictability for funding and operational planning. In a clinical-stage biotech, erratic revenue complicates the ability to cover fixed R&D and administrative costs, increasing reliance on financing and elevating execution risk over the medium term.

Race Oncology Ltd. News

Racura Raises $24.4m as 97% of Piggyback Options Are Exercised

Race Oncology Ltd. ( ($AU:RAC) ) has issued an announcement. Racura Oncology has secured $24.38 million from the...

3d ago

RAC

Racura Oncology Options Lapse, Trimming Potential Equity Dilution

Race Oncology Ltd. ( ($AU:RAC) ) has shared an announcement. Racura Oncology has announced the cessation of 631,201...

3d ago

RAC

Racura Oncology Raises $31.2m as Specialist Investor Takes Strategic Stake

Race Oncology Ltd. ( ($AU:RAC) ) has provided an update. Racura Oncology has secured a binding commitment from...

3d ago

RAC

Racura Oncology Seeks ASX Quotation for Additional Ordinary Shares

Race Oncology Ltd. ( ($AU:RAC) ) just unveiled an update. Racura Oncology has applied to the ASX for...

5d ago

RAC

Racura Oncology Seeks ASX Quotation for Over 1.1 Million New Shares

Race Oncology Ltd. ( ($AU:RAC) ) has issued an announcement. Racura Oncology Ltd has applied to the ASX...

8d ago

RAC

Racura Oncology Plans Share Placement to Fund Oncology Programs

Race Oncology Ltd. ( ($AU:RAC) ) has provided an announcement. Racura Oncology Ltd, an ASX-listed biotech company focused...

9d ago

RAC

Racura Oncology underwrites expiring options to secure $25m for cancer trials

An announcement from Race Oncology Ltd. ( ($AU:RAC) ) is now available. Racura Oncology has secured an underwriting...

9d ago

RAC

Racura Oncology director boosts stake with $500,000 option exercise

Race Oncology Ltd. ( ($AU:RAC) ) has shared an update. Racura Oncology director Daniel Tillett has increased his...

10d ago

RAC

Racura Oncology Seeks ASX Quotation for 1.5 Million New Shares

Race Oncology Ltd. ( ($AU:RAC) ) has issued an update. Racura Oncology has applied to the ASX for...

10d ago

RAC

Racura Oncology Director Boosts Stake With $500,000 Option Exercise

Race Oncology Ltd. ( ($AU:RAC) ) has provided an announcement. Racura Oncology has reported a change in the...

12d ago

RAC

RAC FAQ

What was Race Oncology Ltd.’s price range in the past 12 months?

Race Oncology Ltd. lowest share price was AU$1.11 and its highest was AU$4.90 in the past 12 months.

What is Race Oncology Ltd.’s market cap?

Race Oncology Ltd.’s market cap is AU$538.29M.

When is Race Oncology Ltd.’s upcoming earnings report date?

Race Oncology Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 87 days.

How were Race Oncology Ltd.’s earnings last quarter?

Race Oncology Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.023.

Is Race Oncology Ltd. overvalued?

According to Wall Street analysts Race Oncology Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Race Oncology Ltd. pay dividends?

Race Oncology Ltd. does not currently pay dividends.

What is Race Oncology Ltd.’s EPS estimate?

Race Oncology Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Race Oncology Ltd. have?

Race Oncology Ltd. has 195,033,420 shares outstanding.

What happened to Race Oncology Ltd.’s price movement after its last earnings report?

Race Oncology Ltd. reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.646%.

Which hedge fund is a major shareholder of Race Oncology Ltd.?

Currently, no hedge funds are holding shares in AU:RAC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Race Oncology Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-47.44%

Trailing 12-Months

Asset Growth

14.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Race Oncology Ltd.

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.